1. Home
  2. FVCB vs ZNTL Comparison

FVCB vs ZNTL Comparison

Compare FVCB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FVCBankcorp Inc.

FVCB

FVCBankcorp Inc.

HOLD

Current Price

$18.32

Market Cap

338.0M

Sector

Finance

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$3.78

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FVCB
ZNTL
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
338.0M
289.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
FVCB
ZNTL
Price
$18.32
$3.78
Analyst Decision
Buy
Buy
Analyst Count
1
5
Target Price
$18.00
$6.60
AVG Volume (30 Days)
65.0K
1.0M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
1.80%
N/A
EPS Growth
47.56
18.03
EPS
0.81
N/A
Revenue
$1,781,000.00
N/A
Revenue This Year
$13.83
N/A
Revenue Next Year
$7.45
N/A
P/E Ratio
$22.62
N/A
Revenue Growth
13.87
N/A
52 Week Low
$11.83
$1.21
52 Week High
$19.11
$6.95

Technical Indicators

Market Signals
Indicator
FVCB
ZNTL
Relative Strength Index (RSI) 50.69 41.97
Support Level $18.12 $3.46
Resistance Level $19.07 $4.00
Average True Range (ATR) 0.34 0.19
MACD -0.10 -0.01
Stochastic Oscillator 49.89 38.17

Price Performance

Historical Comparison
FVCB
ZNTL

About FVCB FVCBankcorp Inc.

FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: